dc-806
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 22, 2021 (NCT06808815)
Timeline
Indications
Mechanism of action
- Interleukin 17AANTAGONIST
IL17A antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06092931 | Phase 1 | Oct 16, 2023 | Eli Lilly |
| NCT06045000 | Phase 1 | Sep 14, 2023 | Eli Lilly |
| NCT05994807 | Phase 1 | Aug 8, 2023 | Eli Lilly |
| NCT05896527 | Phase 2 | May 11, 2023 | Eli Lilly |
| NCT06808815 | Phase 1 | Sep 22, 2021 | Eli Lilly |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 5 | 5 | 2 | 2021 |
1 organizations
Page 1 / 1